---
title: "Atrium Therapeutics gets FDA IND clearance for ATR 1072, Corventis Phase 1/2 trial to start"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292678130.md"
description: "Atrium Therapeutics received FDA IND clearance for ATR 1072, enabling the Corventis Phase 1/2 trial for PRKAG2 syndrome. The open-label study will enroll ~37 participants across two parts: Part A for safety/dose selection and Part B for expansion at the recommended dose. Site initiation is underway, with the first participant expected by end of 2026 and initial proof-of-concept data anticipated in H2 2027."
datetime: "2026-07-14T21:23:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292678130.md)
  - [en](https://longbridge.com/en/news/292678130.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292678130.md)
---

# Atrium Therapeutics gets FDA IND clearance for ATR 1072, Corventis Phase 1/2 trial to start

**Atrium Therapeutics announced FDA clearance of its IND for ATR 1072, enabling the Corventis Phase 1/2 trial for PRKAG2 syndrome.**

**Key Highlights:**

-   FDA cleared IND for ATR 1072, allowing initiation of the Corventis Phase 1/2 clinical trial.
-   Corventis is an open-label, multicenter Phase 1/2 study planned to enroll ~37 participants in two parts.
-   Part A will use multiple ascending dose cohorts for safety and dose selection; Part B is a single-arm expansion at the recommended dose.
-   Site initiation is underway; first participant expected by end of 2026, with initial proof-of-concept data anticipated in H2 2027.

Original SEC Filing: Atrium Therapeutics, Inc. \[ RNA \] - 8-K - Jul. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [RNA.US](https://longbridge.com/en/quote/RNA.US.md)

## Related News & Research

- [Wells Fargo Remains a Buy on Atrium Therapeutics, Inc. (RNA)](https://longbridge.com/en/news/292885553.md)
- [Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RNA Stock News](https://longbridge.com/en/news/283429396.md)
- [ATR: Q2 2026 sales rose 6% but margins declined due to higher costs and a less favorable mix](https://longbridge.com/en/news/294534380.md)
- [Fujian Haixi Pharma wins FDA IND clearance for HX9428 Phase II nAMD trial](https://longbridge.com/en/news/294795566.md)
- [04:54 ETEuropas KI-Boom hat ein Problem mit den Inhalten: Die Einführung steigt um 650 %, doch die Grundlage, auf der er basiert, bröckelt](https://longbridge.com/en/news/294330427.md)